June 23, 2014

Cambridge, MA— (BUSINESS WIRE)—June 23, 2014 – ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug safety and pharmacovigilance. 

“As we continue to strengthen our oncology business in the United States and Europe, the recruitment of these three executives to our management team demonstrates our commitment to building a highly successful commercial oncology business,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.  “They exemplify our core values and bring many years of highly relevant experience to ARIAD in areas of fundamental importance to the Company.  I am pleased to welcome Tim, Yan and Piet to ARIAD and look forward to their important contributions to our business.”

Timothy Maines leads the global quality function and has put in place systems to ensure quality and compliance in clinical, manufacturing and laboratory good practices. Mr. Maines brings over twenty years of leadership experience in quality operations and strategy to ARIAD.

Prior to joining ARIAD, Mr. Maines served as vice president, quality at Omthera Pharmaceuticals, where he was responsible for quality and technical GXP operations.  He previously was vice president, corporate quality assurance at MedImmune, LLC, where he oversaw the quality assurance operations team at six GMP manufacturing facilities.  Mr. Maines also was vice president, quality at GTC Biotherapeutics.  

Mr. Maines has a B.S. degree in biology and microbiology from Gannon University.

Yan Moore, M.D. leads global medical affairs and is responsible for investigator-sponsored clinical-research activities, publications, medical information, key therapeutic leader engagement, medical affairs planning for ARIAD’s pipeline of oncology products and in collaboration with others, for life-cycle management of Iclusig® (ponatinib) and strategic planning for its current and future clinical indications.

Prior to joining ARIAD, Dr. Moore served as associate vice president, global medical affairs at Sanofi, where he was responsible for global medical affairs, clinical development and business opportunities for the company’s gastrointestinal and other solid-tumor products.  He previously was executive director, oncology clinical development at GlaxoSmithKline and the cetuximab development group director at Bristol-Myers Squibb (BMS).  He also was gastrointestinal cancer development lead for the oncology portfolio.  Before joining BMS, Dr. Moore headed the medical affairs group at GPC Biotech, Inc. and was the global medical director at GE Healthcare (Oncura, Inc.) for urology and genitourinary oncology products.

Dr. Moore earned B.S. and M.D. degrees from the Sackler School of Medicine in Tel Aviv, Israel. He completed his internship in internal medicine at the Edith Wolfson Medical Center and a residency program in obstetrics and gynecology. He received his M.B.A. from the LeBow College of Business at Drexel University in Philadelphia.

Piet A.M Vervaet, M.D leads global safety and pharmacovigilance and is responsible for safety surveillance, risk identification and risk management for ARIAD’s marketed and pipeline of oncology products, as well as proper risk communications to patients, healthcare professionals and health authorities. He also oversees, in collaboration with others, regulatory compliance with safety legislation for the Company’s products.

Prior to joining ARIAD, Dr. Vervaet served as vice president, drug safety and pharmacovigilance at Onyx Pharmaceuticals, where he was responsible for the strategic leadership and oversight for the pharmacovigilance and drug-safety function and focused on proactive and timely risk-benefit assessments of clinical data to characterize the safety profiles of the company’s oncology portfolio.  He previously held therapeutic-area safety leadership positions at AstraZeneca, where he oversaw the safety of products in various therapeutic areas, including oncology, infectious diseases, gastroenterology, and pulmonology. Before joining AstraZeneca Dr. Vervaet held drug-safety positions in the U.S. and Europe at Johnson and Johnson.

Dr. Vervaet earned his B.S. and M.D. degrees from the University of Ghent in Belgium and completed residency programs at St. Elisabeth Hospital in Sijsele/Damme (Belgium).


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.  ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.  ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.  For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).  


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.